Among over 151,000 patients, use of GLP-1 drugs was linked to a lower risk of death compared with no use (adjusted HR 0.77, ...

A comprehensive review in The Journal of Clinical Investigation finds no overall link between GLP-1 receptor agonists and ...

T hree popular GLP-1 receptor agonists carried similar risks for serious gastrointestinal (GI) events among adults with type ...

An Institute for Clinical and Economic Review report concluded that the GLP-1 drugs tirzepatide and semaglutide (Ozempic, ...

New research presented at ACR 2025 shows GLP-1 receptor agonists, used for diabetes and obesity, may reduce rheumatoid ...

Although findings from a large retrospective study supports these positive effects of taking a GLP-1, it’s unclear whether ...

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide (Victoza®), semaglutide (Ozempic®, Wegovy®), and tirzepatide (Mounjaro®, ...

GLP-1RAs improved RA disease activity, pain scores, weight, cholesterol, and HbA1c levels in patients with a BMI ≥27. Nearly one-third of patients discontinued GLP-1RA therapy due to gastrointestinal ...

People with Type 2 diabetes who combined healthy lifestyle habits with GLP-1 receptor agonist (GLP-1 RA) medications had a greater reduction in risk of major adverse cardiovascular events, including ...

People taking GLP-1 medications had better-controlled asthma overall, though there was no difference in lung function compared to those not taking GLP-1s. The study suggests that GLP-1 drugs may have ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this widespread impact, many sufferers find current preventive treatments ...